IP Library › Granted Patent US 9,617,311
Granted Patent B2
US 9,617,311 · App. 14/656,107 · Granted Apr 11, 2017

Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing

Inventors: Yeou-Ping Tsao (Taipei, TW); Tsung-Chuan Ho (Taipei City, TW)
Assignee: Mackay Memorial Hospital
C07K14/00A61K38/18C07K7/08C12N5/0621C12N5/0623C12N5/0628C12N2501/10C12N2501/998
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,617,311
App. No.
14/656,107
Granted
Apr 11, 2017
Kind
B2
Abstract

Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing.

Claims (24)

1. A synthetic peptide for promoting the proliferation of limbal epithelial stem cells or hair follicle stem cells, wherein,

the amino acid sequence of the synthetic peptide consists of 20-39 amino acid residues in length and has at least 80% amino acid sequence identity to SEQ. ID NO: 1;

the N-terminus of the amino acid sequence is acetylated and the C-terminus of the amino acid sequence is amidated; and

at least 20 consecutive residues of the synthetic peptide has at least 90% amino add sequence identity to residues 11-30 of SEQ ID NO: 1 and comprises four consecutive residues identical to residues 11-14 (SLGA) of SEQ ID NO: 1.

2. The synthetic peptide of claim 1 , wherein the amino acid sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5.

3. A composition for promoting the proliferation of limbal epithelial stem cells or hair follicle stem cells, comprising,

an effective amount of the synthetic peptide of claim 1 , and

a carrier.

4. The composition of claim 3 , wherein the carrier is a powdered culture medium suitable for culturing the stem cells.

5. The composition of claim 4 , wherein the synthetic peptide is present in an amount of 1-100 nM.

6. The composition of claim 5 , wherein the synthetic peptide is present in an amount of 25-50 nM.

7. The composition of claim 3 , wherein the carrier is a pharmaceutically acceptable carrier selected from the group consisting of a liquid, gel, cream, ointment, adhesive, amniotic membrane, skin substitute, artificial skin, and skin equivalents.

8. The composition of claim 3 , wherein the amino acid sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5.

9. A composition for promoting the proliferation of limbal epithelial stem cells or hair follicle stem cells, comprising,

an effective amount of a synthetic peptide, wherein the amino acid sequence of the synthetic peptide consists of 20-39 amino acid residues in length and has at least 80% amino acid sequence identity to SEQ ID NO: 1, and at least 20 consecutive residues of the synthetic peptide has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1 and comprises four consecutive residues identical to residues 11-14 (SLGA) of SEQ ID NO: 1; and

a pharmaceutically acceptable carrier selected from the group consisting of a gel, cream, and ointment.

10. The composition of claim 9 , wherein the amino acid sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5.

11. The composition of claim 9 , further comprising an antibiotic and/or antimycotic agent.

12. A composition for promoting skin or corneal wound healing, comprising,

an effective amount of a synthetic peptide consisting of an amino acid sequence that is 20-39 amino acid residues in length and has at least 80% amino acid sequence identity to SEQ ID NO: 1, and at least 20 consecutive residues of the synthetic peptide has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1 and comprises four consecutive residues identical to residues 11-14 (SLGA) of SEQ ID NO: 1;

an antibiotic and/or antimycotic agent; and

a pharmaceutically acceptable carrier.

13. The composition of claim 12 , wherein the carrier is a pharmaceutically acceptable carrier selected from the group consisting of a liquid, gel, cream, ointment, adhesive, amniotic membrane, skin substitute, artificial skin, and skin equivalents.

14. The composition of claim 12 , wherein the amino acid sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5.

Priority Claims (1)
TW 100109945 A · Mar 23, 2011 · national
Continuity (2)
Division 13428996 · Mar 23, 2012
Related Publication 20150183832A1 · Jul 2, 2015